Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line.
Aldosterone effects are mediated by the mineralocorticoid receptor (MR), a transcription factor highly expressed in the distal nephron. Given that MR expression level constitutes a key element controlling hormone responsiveness, there is much interest in elucidating the molecular mechanisms governing MR expression. To investigate whether hyper- or hypotonicity could affect MR abundance, we established by targeted oncogenesis a novel immortalized cortical collecting duct (CCD) cell line and examined the impact of osmotic stress on MR expression. KC3AC1 cells form domes, exhibit a high transepithelial resistance, express 11beta-hydroxysteroid dehydrogenase 2 and functional endogenous MR, which mediates aldosterone-stimulated Na(+) reabsorption through the epithelial sodium channel activation. MR expression is tightly regulated by osmotic stress. Hypertonic conditions induce expression of tonicity-responsive enhancer binding protein, an osmoregulatory transcription factor capable of binding tonicity-responsive enhancer response elements located in MR regulatory sequences. Surprisingly, hypertonicity leads to a severe reduction in MR transcript and protein levels. This is accompanied by a concomitant tonicity-induced expression of Tis11b, a mRNA-destabilizing protein that, by binding to the AU-rich sequences of the 3'-untranslated region of MR mRNA, may favor hypertonicity-dependent degradation of labile MR transcripts. In sharp contrast, hypotonicity causes a strong increase in MR transcript and protein levels. Collectively, we demonstrate for the first time that optimal adaptation of CCD cells to changes in extracellular fluid composition is accompanied by drastic modification in MR abundance via transcriptional and posttranscriptional mechanisms. Osmotic stress-regulated MR expression may represent an important molecular determinant for cell-specific MR action, most notably in renal failure, hypertension, or mineralocorticoid resistance.
Viengchareun
Say
S
INSERM, Le Kremlin Bicêtre, France.
Kamenicky
Peter
P
Teixeira
Marie
M
Butlen
Daniel
D
Meduri
Geri
G
Blanchard-Gutton
Nicolas
N
Kurschat
Christine
C
Lanel
Aurélie
A
Martinerie
Laetitia
L
Sztal-Mazer
Shoshana
S
Blot-Chabaud
Marcel
M
Ferrary
Evelyne
E
Cherradi
Nadia
N
Lombès
Marc
M
D000450:Aldosterone / Q000494:pharmacology*; D000818:Animals; D015153:Blotting, Western; D002460:Cell Line; D024202:Electrophoretic Mobility Shift Assay; D005786:Gene Expression Regulation / Q000187:drug effects; D006982:Hypertonic Solutions / Q000494:pharmacology; D007038:Hypotonic Solutions / Q000494:pharmacology; D007150:Immunohistochemistry; D017136:Ion Transport / Q000187:drug effects; D007685:Kidney Tubules, Collecting / Q000166:cytology; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009995:Osmosis / Q000187:drug effects* / Q000502:physiology*; D055550:Protein Stability; D018161:Receptors, Mineralocorticoid / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012964:Sodium / Q000378:metabolism; D014162:Transfection
D006982:Hypertonic Solutions; D007038:Hypotonic Solutions; D018161:Receptors, Mineralocorticoid; D000450:Aldosterone; D012964:Sodium